Takeda Pharmaceutical Co Ltd reports results for the quarter ended June 30 - Earnings Summary

Takeda Pharmaceutical

30/07/2026 13:30

Takeda Pharmaceutical Co Ltd 4502.T reported quarterly adjusted earnings of JPY70.54​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of JPY79.40.  The mean expectation of four analysts for the quarter was for earnings of JPY54.38 per share. Wall Street expected results to range from JPY46.60  to JPY59.64 per share.
Revenue rose 10.2% to JPY1.22 trillion from a year ago; analysts expected JPY1.15 trillion. 
Takeda Pharmaceutical Co Ltd's reported EPS for the quarter was JPY70.54​.
The company reported quarterly net income of JPY113.2 billion.
Takeda Pharmaceutical Co Ltd shares had risen by 13.4% this quarter and gained 20.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 12.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Takeda Pharmaceutical Co Ltd is JPY6,350.00, about 10% above its last closing price of JPY5,718.00
This summary was machine generated from LSEG data July 30 at 12:30 p.m. UTC. ​All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
153.72 billion
201.42 billion
Beat
Mar. 31 2026 
6.38 billion
-13.62 billion
Missed
Dec. 31 2025 
163.90 billion
168.82 billion
Beat
Sep. 30 2025 
130.97 billion
142.74 billion
Beat